Send me real-time posts from this site at my email
Chris Lau

Bet against Gene-Editing Stocks

Sangamo Therapeutics $SGMO rewarded shorts, who number 13.5% in shares short float, after ZFN data showed only a small increase in IDS, an enzyme.

$SGMO, SANGAMO THERAPEUTICS INC / H1

Conceptually, gene editing is an incredible science but practically, failure rate is high.  SGMO's results are worse because it has yet to prove itself in a human subject.

$CRSP stock fell in sympathy with $SGMO's news but it has its own risks. It is competing with $BLUE in the gene-editing space.

$CRSP, CRISPR THERAPEUTICS AG / H1

$BLUE, BLUEBIRD BIO INC / H1

Still,  BLUE is hardly even competitive. itis getting conditional approval in EU but the EU might ask Bluebird to run a pivotal with a comparator arm. Blue mustshow lentiglobin is better than existing cures (SCT). Lentiglobin works only in non-B0B0 pts.

Editas Medicine $EDIT lost its CEO, who will leave on March 1, per the Jan 22 announcement.

$EDIT, EDITAS MEDICINE INC / H1

Gene-editing is a messy sector.

Though bears who already did so are ahead, It is ripe for more short-selling.